Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DGX
STRONG BUYFLAGQuest Diagnostics Incorporated · Healthcare · United States · $25.1B · Avg Vol: $244M/d
Quest Diagnostics has quality Q63 and momentum M69, but value sits exactly on the floor at V50, missing the all-three-above-60 path, and the only filing is insider selling, so there is no corroboration.
COMPANY DESCRIPTION
Quest Diagnostics Incorporated provides diagnostic information services, including a broad range of routine and advanced clinical laboratory testing, medical drug testing, and anatomical pathology services. The company's competitive advantage is its extensive network of patient service centers and laboratories, a wide test menu, and strong brand reputation in diagnostic testing. Quest Diagnostics is a leading global provider of diagnostic information services, crucial for healthcare decision-making.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.9B | 9.3B | 9.9B | 11.0B | 3.7% | 11.3B | 12.0B | 12.5B | 6.4% |
| EPS | 8.10 | 7.59 | 7.78 | 8.87 | 3.1% | 8.93 | 9.95 | 10.73 | 10.0% |
| Shares | 111.0M | 111.4M | 110.6M | 110.2M | -0.7% | 110.7M | — | — | — |
| Debt | 4.7B | 5.5B | 7.1B | 6.6B | 11.8% | 6.4B | — | — | — |
| Equity | 5.9B | 6.3B | 6.8B | 7.2B | 6.8% | — | — | — | — |
| Op CF | 1.7B | 1.3B | 1.3B | 1.9B | 3.2% | 1.9B | — | — | — |
| Inv CF | -543.0M | -1.1B | -2.5B | -631.0M | — | — | — | — | — |
| Fin CF | -1.7B | 160.0M | 1.1B | -1.4B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DGX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DGX | Quest Diagnostics Incorporated(you) | $25.1B | 89 | STRONG BUY |
| LH | Labcorp Holdings Inc. | $24.3B | 90 | STRONG BUY |
| ILMN | Illumina, Inc. | $29.4B | 83 | STRONG BUY |
| A | Agilent Technologies, Inc. | $32.5B | 77 | BUY |
| MEDP | Medpace Holdings, Inc. | $16.8B | 77 | BUY |
| IQV | IQVIA Holdings Inc. | $34.7B | 69 | BUY |
| WAT | Waters Corporation | $36.8B | 65 | HOLD |
| CRL | Charles River Laboratories International, Inc. | $10.9B | 69 | BUY |
| RVTY | Revvity, Inc. | $12.3B | 64 | HOLD |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 60 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.6%